OrphanPulse Wk 30: CHMP Backs a Drug It Refused Twice
Five regulatory milestones landed in rare disease in a single week, led by a committee recommending approval for a drug it had refused twice. Underneath the filing queue sat a harder story: the largest disease-modification trial ever run in biliary atresia failed, in the same week a six-year-old received the world’s first liver transplant through a single robotic incision. When medicine cannot modify a disease, surgery carries it.
developments
milestones
designations
failure
first
CHMP has recommended approval for a drug it refused twice, and cerebral ALD gets its first medicine
The most consequential rare-disease decision this week reverses one the same committee made two years ago. On 24 July the EMA’s CHMP recommended marketing authorisation under exceptional circumstances for Nezglyal (leriglitazone) in male patients aged 2 to 12 with cerebral adrenoleukodystrophy and gadolinium-negative brain lesions, with European Commission approval expected by the end of September. The same committee recommended refusal in February 2024 and upheld that refusal in May 2024 after re-examination, citing weight gain, oedema and an unfavourable benefit-risk balance. What changed was not the argument, it was the evidence: Minoryx and Neuraxpharm went back with the completed 96-week Phase 2/3 NEXUS study in paediatric patients plus real-world data from compassionate use, and filed again. Read past the corporate persistence and the clinical point is larger. cALD is a devastating childhood neurodegenerative disease whose only meaningful interventions have been stem cell transplant or gene therapy, both requiring a matched window and carrying real procedural risk. An oral, brain-penetrant option changes who is treatable, particularly outside centres equipped for transplant. Note the narrowness of the recommended label, ages 2 to 12, gadolinium-negative lesions, exceptional circumstances, which is the committee granting exactly as much as the evidence supports and no more.
Dyne’s exon 51 Duchenne therapy takes Priority Review and a January 2027 date, then raises $375 million the next day
The FDA accepted Dyne Therapeutics’ BLA for z-rostudirsen (DYNE-251) in Duchenne muscular dystrophy amenable to exon 51 skipping, granting Priority Review with a PDUFA target action date of 21 January 2027. The filing seeks Accelerated Approval on dystrophin as a surrogate endpoint, supported by the registrational expansion cohort of the Phase 1/2 DELIVER trial, which met its primary endpoint with statistically significant dystrophin production on four-weekly dosing and functional improvement across multiple endpoints. The confirmatory Phase 3 FORZETTO trial is already running, which matters, because accelerated approvals in DMD have been contentious precisely where confirmatory work lagged. The commercially instructive part came a day later: Dyne priced an upsized $375 million public offering. A regulatory milestone is the cheapest capital-raising window a clinical-stage company gets, and this one was used within 24 hours.
BridgeBio’s encaleret NDA accepted for autosomal dominant hypocalcemia type 1
The FDA accepted BridgeBio’s new drug application for encaleret in ADH1, a rare genetic disorder of calcium regulation with no approved targeted therapy. The pattern is the one BridgeBio has built its structure around: a portfolio of genetically defined rare diseases, each run as a discrete programme, each aiming at a small but clearly identified population. Acceptance is procedural rather than substantive, but in an indication with no approved option the filing itself sets a first-mover position that is difficult to displace later.
Monopar begins a rolling NDA submission for ALXN1840 in Wilson disease
Monopar started a rolling submission for ALXN1840, an asset originally developed at Alexion, in Wilson disease, an inherited copper-metabolism disorder. Rolling submission means modules are filed as completed rather than as a single package, which shortens the interval between finishing the work and starting the clock. The asset history is the part worth logging: a large-company programme finding a second life at a small-cap is a recurring rare-disease pattern, and it usually means the economics did not clear a big-pharma hurdle rate rather than that the science failed.
Zevra updates on the regulatory path for arimoclomol
Zevra Therapeutics issued an update on its regulatory submission for arimoclomol, its Niemann-Pick disease type C asset. Regulatory updates that arrive as standalone releases rather than inside quarterly results usually carry timing news rather than approval news, so treat the substance as procedural until the detail is confirmed. Worth tracking as a dated item rather than a result.
Ipsen’s Phase 3 fails in biliary atresia, the disease that fills paediatric transplant lists
Ipsen reported that BOLD, the largest trial ever run in disease modification for biliary atresia, did not meet its primary endpoint. The design was serious: 254 patients across 19 countries, all having undergone Kasai portoenterostomy within 90 days of birth, randomised to odevixibat 120mcg/kg/day or placebo for up to 104 weeks, with native liver survival, defined as time to transplant or death at week 104, as the primary endpoint. Safety was consistent with the drug’s approved indications. Biliary atresia remains the leading cause of paediatric liver transplant, frequently before a child’s second birthday, with no medical option beyond surgery. Ipsen’s R&D head called the disease one that has so far evaded every therapeutic attempt beyond surgery, which is an unusually direct summary of where the field stands. The read for anyone modelling paediatric hepatology: odevixibat works in PFIC and Alagille syndrome, so this is not a failed molecule, it is a failed extension into a disease whose mechanism is structural rather than bile-acid driven.
A father’s liver, one incision, and the surgery that biliary atresia keeps demanding
In the same week Ipsen’s medical option failed, King Faisal Specialist Hospital in Riyadh performed the world’s first liver transplant through a single robotic incision, in a six-year-old boy with Wolcott-Rallison syndrome whose father donated the left lobe of his liver. The programme behind it is substantial: 165 robotic liver transplants since the 2023 world first, on more than 1,700 robotic living-donor resections, with the first three single-port donor operations averaging 272 minutes against a 430-minute benchmark, 25ml blood loss and two to three day donor discharge. Put the two stories side by side and the week’s structural point emerges. When medicine cannot yet modify a disease, the burden falls on surgery, and the variable that governs how many children get transplanted is not surgical skill but how much a living donor is asked to endure.
Agios updates on the Phase 2 trial of tebapivat in sickle cell disease
Agios issued a standalone update on its Phase 2 study of tebapivat in sickle cell disease. As with any mid-study update released on its own rather than through results, the specifics determine whether this is a design change, an enrolment note or a discontinuation, so mark it as a development to confirm rather than a readout. Agios has a genuine franchise in PK activation, so the programme’s direction carries weight beyond the single asset.
Healx doses the first patient in a Phase 1/2 trial of an AI-derived rare-disease candidate
Healx dosed its first patient in a Phase 1/2 study, moving an AI-discovered rare-disease programme into the clinic. First-in-human is a starting gun rather than a result, and should be logged that way. The reason it is worth logging at all is the provenance: computational rare-disease discovery has generated a great deal of claim and very few dosed patients, and the value of this milestone is that it converts a platform argument into a clinical fact that can eventually be judged.
China approves the world’s first once-daily oral Factor B inhibitor, and a US small-cap holds the ex-China rights
China’s NMPA approved Haisco’s ciprocopan for adults with paroxysmal nocturnal haemoglobinuria who are complement-inhibitor-naive, the world’s first once-daily oral complement Factor B inhibitor and Haisco’s fifth approved innovative drug. The competitive case sits in Haisco’s own framing: C5 inhibitors control intravascular haemolysis without touching upstream complement activation, and twice-daily oral regimens carry breakthrough haemolysis risk. The structural point is bigger than the mechanism. Nuvectis Pharma, a small US-listed company, licensed rights outside Greater China, India and parts of Southeast Asia one month before this approval landed, buying a substantially de-risked asset immediately ahead of its first regulatory validation. That is the flow our H1 data described at scale, with China selling $92.6 billion of assets westward across 45 deals while buying $13.3 billion.
Crysvita reaches one-month-old infants in the EU, and buys two more years of orphan exclusivity
The European Commission approved expanding Crysvita (burosumab) to infants from one month to one year of age with X-linked hypophosphataemia, following April’s CHMP opinion and supported by the Phase 1/2 BUR-CL207 study. The clinical case is real, XLH damages bone mineralisation from the earliest months, so treating at one month rather than twelve changes outcomes rather than labels. The commercial case runs alongside it: the same approval extends EU orphan market exclusivity by two years, from February 2028 to February 2030. Paediatric extension is the most dependable lifecycle play in rare disease, and it is unusual for the clinical and commercial arguments to align this cleanly.
Atsena takes two EMA orphan designations in one week for its ocular gene therapies
Atsena Therapeutics received EMA orphan designation for both ATSN-101 and ATSN-201, its retinal gene therapy candidates. A single designation is routine, two at once is a portfolio signal: it says the platform is generating multiple programmes that clear the same regulatory threshold, which is what separates a gene therapy company from a gene therapy asset.
Affinia wins FDA orphan designation for a gene therapy in BAG3-associated dilated cardiomyopathy
The FDA granted orphan drug designation to Affinia Therapeutics’ AFTX-201 for BAG3-associated dilated cardiomyopathy, an inherited form of heart failure caused by a single gene. Genetic cardiomyopathies are a frontier where gene therapy has a clean rationale, one gene, one identifiable population, and a disease course that currently ends in transplant or device. Early, and a designation is not a result, but the target selection is sound.
Inhibikase receives FDA orphan designation for IKT-001 in pulmonary arterial hypertension
Inhibikase Therapeutics was granted orphan drug designation for IKT-001 in PAH. Designation confers development incentives and exclusivity potential, not evidence of benefit, and PAH is a comparatively crowded rare indication with several approved mechanisms. Log it as a portfolio marker.
OMEICOS clears an end-of-Phase-2 meeting and heads for Phase 3 in primary mitochondrial disease
OMEICOS reported a positive end-of-Phase-2 meeting with the FDA for OMT-28 in primary mitochondrial diseases, clearing the path to a Phase 3 programme. Primary mitochondrial disease has defeated repeated therapeutic attempts and has almost no approved options, so reaching alignment with the agency on a pivotal design is itself a meaningful step in an indication where trial design, not molecule supply, has been the recurring obstacle.
Rinascera launches with two rare genetic skin disease programmes
Rinascera Therapeutics emerged with two candidates in rare genetic skin diseases. New rare-disease company formations are worth tracking as a leading indicator of where capital believes the regulatory and pricing environment still works, and dermatologic rare disease has been comparatively under-served relative to neurology and metabolic disease.
Broad, Boston Children’s and Jackson Laboratory launch a centre for therapeutic genetics
Three of the strongest genetics institutions in the United States established a joint Center for Therapeutic Genetics. Infrastructure announcements rarely move markets, but they shape what becomes possible three to five years out, and the recurring bottleneck in ultra-rare disease is not target identification, it is having a route from a diagnosed child to a manufacturable therapy. That is the gap this kind of institution exists to close.
This week is what happened. Catalyst and AccessWatch are what comes next.
The weekly Pulse closes the loop on the last seven days. The monthly beats open the next ninety.